FDA Issues Clinical Hold On Dyne's IND For Duchenne Muscular Dystrophy Program

The FDA has placed a clinical hold on Dyne Therapeutics Inc's DYN investigational New Drug (IND) application to initiate a clinical trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) amenable to skipping exon 51. 

  • Dyne received a clinical hold letter from the FDA on Friday, January 14, requesting additional clinical and non-clinical information for DYNE-251. 
  • The Company expects to submit to the FDA its response with data from existing and ongoing studies in Q2 of 2022.
  • Related: Dyne Therapeutics Highlights New Preclinical Data For Duchenne Muscular Dystrophy Program.
  • If satisfactory to the FDA, dosing patients in a Phase 1/2 multiple ascending dose trial of DYNE-251 by mid-2022 per its current guidance.
  • As previously announced, the Company expects to submit an IND for DYNE-101 in myotonic dystrophy type 1 (DM1) during Q1 of 2022 and dosing patients in a planned MAD clinical trial mid-2022.
  • Price Action: DYN shares are down 15.1% at $7.89 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsShort IdeasHealth CareSmall CapFDAMoversTrading IdeasGeneralBriefsDuchenne Muscular Dystrophywhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!